Details

Autor(en) / Beteiligte

• Maemondo, Makoto
• Inoue, Akira
• Kobayashi, Kunihiko
• Sugawara, Shunichi
• Oizumi, Satoshi
• Isobe, Hiroshi
• Gemma, Akihiko
• Harada, Masao
• Harada, Toshiyuki
• Yoshizawa, Hirohisa
• Kinoshita, Ichiro
• Fujita, Yuka
• Okinaga, Shoji
• Hirano, Haruto
• Yoshimori, Kozo
• Ogura, Takashi
• Ando, Masahiro
• Miyazawa, Hitoshi
• Tanaka, Tomoaki
• Saijo, Yasuo
• Hagiwara, Koichi
• Morita, Satoshi
• Nukiwa, Toshihiro

Titel

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Ist Teil von

• The New England journal of medicine, 2010-06, Vol.362 (25), p.2380-2388

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2010

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Previously untreated patients with non–small-cell lung cancer expressing mutated epidermal growth factor receptors (EGFRs) were randomly assigned to receive either the EGFR kinase inhibitor gefitinib or carboplatin plus paclitaxel. The gefitinib group had a significantly higher rate of complete response (73.7%, vs. 30.7% in the standard-chemotherapy group) and significantly longer survival (median, 30.5 months, vs. 23.6 months). Thus, defining the small subgroup of patients with EGFR mutations prospectively has important treatment implications. Patients with non–small-cell lung cancer expressing mutated epidermal growth factor receptors (EGFRs) were randomly assigned to receive either the EGFR kinase inhibitor gefitinib or carboplatin plus paclitaxel. The gefitinib group had a significantly higher rate of complete response and significantly longer survival. Non–small-cell lung cancer is a major cause of death from cancer. The use of cytotoxic chemotherapy is associated with a response rate of 20 to 35% and a median survival time of 10 to 12 months among patients with advanced non–small-cell lung cancer. 1 , 2 Gefitinib is an orally administered tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR). In two phase 2 studies of patients with previously treated non–small-cell lung cancer, the response rate was 9 to 19%. 3 , 4 In subsequent phase 3 trials, the noninferiority of gefitinib as compared with docetaxel with respect to overall survival was shown . . .